Equities
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)6,340.00
  • Today's Change20.00 / 0.32%
  • Shares traded876.42k
  • 1 Year change+79.15%
  • Beta0.8202
Data delayed at least 20 minutes, as of Nov 21 2024 15:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

  • Revenue in ILS (TTM)62.59bn
  • Net income in ILS-3.71bn
  • Incorporated1944
  • Employees35.00k
  • Location
    Teva- Pharmaceutical Industries Ltd.124 Dvora Hanevi'a St.TEL AVIV-YAFO 6944020IsraelISR
  • Phone+972 39148213
  • Fax+972 39234050
  • Websitehttps://www.tevapharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hansoh Pharmaceutical Group Company Ltd6.24bn2.43bn50.89bn9.10k21.173.5319.288.150.84370.84372.165.060.38041.813.891,425,881.0014.8211.5817.8713.9891.0190.7838.9729.287.81--0.004312.757.695.5226.8511.49-10.45--
Incyte Corp15.23bn121.38m51.15bn2.52k507.684.32113.353.360.140.1418.7916.450.7154.235.761,614,842.000.56989.070.740411.0293.3794.970.796913.681.82--0.010.008.8714.4575.4240.41-15.06--
Cipla Ltd11.74bn1.98bn52.64bn27.76k26.574.1921.514.4855.3955.39328.19351.200.8031.585.089,549,060.0013.5810.0916.4412.4067.0158.6316.9212.662.8269.410.01621.3913.289.5147.1021.9620.6834.08
Royalty Pharma plc8.47bn4.28bn57.73bn89.0010.252.2621.536.822.562.563.8011.630.1337--72.1525,460,710.0010.119.5713.3012.42----75.6467.80----0.425823.475.245.582,549.50-3.8050.99--
Viatris Inc56.23bn-3.30bn58.56bn38.00k--0.79188.211.04-0.7389-0.738912.5416.580.32192.234.94396,013.20-1.890.0887-2.230.106142.4940.29-5.870.28910.96152.370.443560.11-5.146.17-97.37-30.53-16.88--
Astellas Pharma Inc42.60bn1.32bn68.41bn14.75k51.701.8411.351.6130.4230.42986.34854.610.50601.363.39120,113,500.001.564.592.316.6181.7880.533.097.980.862315.320.377486.615.604.19-82.73-40.179.6213.00
Divi's Laboratories Ltd3.82bn813.20m69.38bn17.50k85.3411.4270.5018.1969.1469.14324.44516.710.57681.134.274,922,286.0012.2916.5513.3218.2259.9156.2421.3126.384.80--0.000634.320.99769.66-12.253.416.4713.40
Teva Pharmaceutical Industries Ltd62.59bn-3.71bn71.47bn35.00k--3.16--1.14-3.26-3.2655.5319.970.40012.054.901,788,132.00-2.99-3.14-4.34-4.2951.0148.14-7.46-9.870.60564.720.7483--6.17-3.4277.15---4.17--
Sandoz Group AG-422.61bn-422.61bn74.28bn23.85k--2.32----------17.20------------------------0.7401--0.3469--7.23---90.92------
Bayer AG184.15bn-3.47bn75.65bn100.87k--0.62832.650.4108-0.8957-0.895747.5831.110.4171.494.49468,688.30-0.7815-1.79-1.06-2.3857.1459.02-1.87-4.800.80592.970.5728---6.115.33-170.87--1.19-47.66
Zhangzhou Pientzhng Phrmctcl Co Ltd5.63bn1.59bn76.88bn2.79k48.4110.63--13.675.105.1018.0823.240.64011.6714.663,911,417.0018.2218.8222.5123.9143.9146.5528.4627.983.64--0.074736.4915.6916.1113.1519.6013.8331.06
Biogen Inc35.90bn6.04bn84.94bn7.57k14.101.3810.042.3711.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Data as of Nov 21 2024. Currency figures normalised to Teva- Pharmaceutical Industries Ltd.'s reporting currency: Israeli Shekel ILS

Institutional shareholders

9.23%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202436.31m3.21%
Norges Bank Investment Managementas of 30 Jun 202434.90m3.08%
KSM Mutual Funds Ltd.as of 31 Jul 20249.36m0.83%
Meitav Mutual Funds Ltd.as of 31 Jul 20248.73m0.77%
Migdal Mutual Funds Ltd.as of 31 Jul 20244.13m0.37%
Harel Mutual Funds Ltd.as of 31 Jul 20243.40m0.30%
Charles Schwab Investment Management, Inc.as of 07 Nov 20242.52m0.22%
Canada Pension Plan Investment Boardas of 31 Mar 20242.48m0.22%
Psagot Mutual Funds Ltd.as of 31 Jul 20241.59m0.14%
Vanguard Global Advisers LLCas of 30 Sep 20241.16m0.10%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.